USFDA approved Finasteride, Tadalafil for new treatment for Benign Prostatic Hyperplasia

Entadfi will be marketed and distributed by Veru’s own direct to patient telemedicine and telepharmacy services platform.

Picture: Pixabay

Last Updated on December 18, 2021 by The Health Master

Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer, announced today that the U.S. Food and Drug Administration (USFDA) has approved Entadfi for the treatment of urinary tract symptoms caused by an enlarged prostate called benign prostatic hyperplasia (BPH).

Entadfi (finasteride and tadalafil) capsule for oral use has also been shown to be more effective in treating urinary tract symptoms caused by BPH with less potential for adverse sexual side effects compared to finasteride monotherapy.

Entadfi dosing is one capsule orally once a day, and the USFDA approved indication is to initiate treatment of the signs and symptoms of benign prostatic hyperplasia in men with an enlarged prostate for up to 26 weeks.

Entadfi will be marketed and distributed by Veru’s own direct to patient telemedicine and telepharmacy services platform.

Veru has also partnered with GoodRx®, a US based digital resource for healthcare, to reach their almost 20 million monthly visitors, which include both consumers and healthcare providers, and offer a unique cash price to ensure our treatment is more affordable and accessible.

USFDA approval of Entadfi, a new treatment for BPH, is a significant execution milestone for Veru and an important step in expanding revenues from our commercial Sexual Health Division.

We use these revenues to invest in and advance our late clinical stage oncology drug pipeline portfolio as well as our global Phase 3 C-19 clinical study,” said Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer.

“We are in the process of augmenting our marketing and sales efforts by adding commercialization partners in the US and ex-US. We expect to begin commercialization in early calendar year 2022.

The treatment of BPH is an annual multi-billion dollar market with over 45 million US prescriptions filled each year and is projected to continue to grow with an aging male population. ”

USFDA approves generic drug for Blood Pressure

Sun Pharma gets USFDA nod for Generic Amphotericin B Liposome Injection

USFDA nod to Dr Reddys Lab for VeraRing

USFDA approves Eye Drops that could replace reading glasses

Zydus Cadila gets USFDA nod for generic Schizophrenia drug

Alembic gets USFDA tentative nod for drug for high BP

Govt notifies NIB, Noida as CDL to test Covid-19 vaccines

USFDA issues Form 483 to Alembic Pharma Gujarat plant

Pharma Manufacturing & Packaging Congress to be held in June 2022

USFDA approves generic drug for Blood Pressure

FDA Haryana and police unearthed a unit manufacturing spurious cosmetics

In-service Pharmacists authorised to dispense drugs for these 8 common ailments

Recruitment of 87 Drug Inspectors put on hold in Maharashtra

NDPS: 9 arrested for selling drugs

Procedure for registration of Medical Devices: CDSCO

Latest Notifications regarding Pharmaceuticals

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
YouTube Icon

Enter your email address:

Delivered by FeedBurner